share_log

AstraZeneca | 6-K: Voydeya Recommended for Approval in the Eu by CHMP as Add-On Treatment to Ravulizumab or Eculizumab for Adults with PNH Who Have Residual Haemolytic Anaemia

AstraZeneca | 6-K: Voydeya Recommended for Approval in the Eu by CHMP as Add-On Treatment to Ravulizumab or Eculizumab for Adults with PNH Who Have Residual Haemolytic Anaemia

阿斯利康 | 6-K:CHMP建議歐盟批准Voydeya作爲Ravulizumab或Eculizumab的附加療法用於患有殘餘溶血性貧血的PNH成人
SEC announcement ·  02/26 06:25
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息